SI1608346T1 - Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe - Google Patents
Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabeInfo
- Publication number
- SI1608346T1 SI1608346T1 SI200430969T SI200430969T SI1608346T1 SI 1608346 T1 SI1608346 T1 SI 1608346T1 SI 200430969 T SI200430969 T SI 200430969T SI 200430969 T SI200430969 T SI 200430969T SI 1608346 T1 SI1608346 T1 SI 1608346T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- acid ester
- hydroxy acid
- methods
- drug delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/403,071 US20040191207A1 (en) | 2003-03-31 | 2003-03-31 | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
EP04759681A EP1608346B1 (en) | 2003-03-31 | 2004-03-19 | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
PCT/US2004/008417 WO2004093851A1 (en) | 2003-03-31 | 2004-03-19 | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1608346T1 true SI1608346T1 (sl) | 2009-04-30 |
Family
ID=32989847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200430969T SI1608346T1 (sl) | 2003-03-31 | 2004-03-19 | Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040191207A1 (sl) |
EP (1) | EP1608346B1 (sl) |
JP (2) | JP5005339B2 (sl) |
AT (1) | ATE413865T1 (sl) |
CA (1) | CA2518918C (sl) |
CY (1) | CY1108700T1 (sl) |
DE (1) | DE602004017705D1 (sl) |
DK (1) | DK1608346T3 (sl) |
ES (1) | ES2317017T3 (sl) |
MX (1) | MXPA05010607A (sl) |
PL (1) | PL1608346T3 (sl) |
PT (1) | PT1608346E (sl) |
SI (1) | SI1608346T1 (sl) |
WO (1) | WO2004093851A1 (sl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050238672A1 (en) * | 2004-04-27 | 2005-10-27 | Nimni Marcel E | Antifungal drug delivery |
DE102010013064A1 (de) | 2010-03-26 | 2011-12-15 | Gabriele Blume | Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut |
HUE055562T2 (hu) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
AU2018374029B2 (en) | 2017-11-27 | 2024-01-11 | Umecrine Cognition Ab | Pharmaceutical formulation of 3a-ethynyl-3B-hydroxyandrostan-17-one oxime |
US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492325A (en) * | 1967-03-24 | 1970-01-27 | Procter & Gamble | Production of alpha-hydroxy acids and esters |
US5002771A (en) * | 1989-02-06 | 1991-03-26 | Rorer Pharmaceutical Corp. | Calcitonin suppository formulations |
CZ278863B6 (en) * | 1992-09-07 | 1994-07-13 | Galena | Medicinal preparations with n-methylated cyclic undecapeptides |
US5455353A (en) * | 1993-03-24 | 1995-10-03 | Hoffmann-La Roche Inc. | 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5430021A (en) * | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
KR0167613B1 (ko) * | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
JPH1081621A (ja) * | 1996-04-01 | 1998-03-31 | Takeda Chem Ind Ltd | 経口投与用医薬組成物 |
CA2185600A1 (en) * | 1996-09-16 | 1998-03-17 | Bernard Charles Sherman | Water-soluble concentrates containing cyclosporins |
GB9621990D0 (en) * | 1996-10-22 | 1996-12-18 | Scotia Pharma Ltd | Use |
WO1999001120A1 (en) * | 1997-07-01 | 1999-01-14 | Pfizer Products Inc. | Solubilized sertraline compositions |
KR100587551B1 (ko) * | 1997-12-10 | 2006-06-08 | 싸이클로스포린 테라퓨틱스 리미티드 | 오메가-3 지방산 오일을 함유하는 약학 조성물 |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
WO2000067728A2 (de) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Lipidpartikel auf der basis von mischungen von flüssigen und festen lipiden und verfahren zu ihrer herstellung |
JP2005505491A (ja) * | 1999-06-02 | 2005-02-24 | ヘキサル・アクチェンゲゼルシャフト | 水溶性活性物質の鼻腔内投与用医薬組成物 |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
DE19943678A1 (de) * | 1999-09-13 | 2001-03-15 | Beiersdorf Ag | Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
GB0118300D0 (en) * | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
-
2003
- 2003-03-31 US US10/403,071 patent/US20040191207A1/en not_active Abandoned
-
2004
- 2004-03-19 JP JP2006507360A patent/JP5005339B2/ja not_active Expired - Fee Related
- 2004-03-19 DE DE602004017705T patent/DE602004017705D1/de not_active Expired - Lifetime
- 2004-03-19 ES ES04759681T patent/ES2317017T3/es not_active Expired - Lifetime
- 2004-03-19 PL PL04759681T patent/PL1608346T3/pl unknown
- 2004-03-19 SI SI200430969T patent/SI1608346T1/sl unknown
- 2004-03-19 CA CA2518918A patent/CA2518918C/en not_active Expired - Fee Related
- 2004-03-19 DK DK04759681T patent/DK1608346T3/da active
- 2004-03-19 MX MXPA05010607A patent/MXPA05010607A/es active IP Right Grant
- 2004-03-19 PT PT04759681T patent/PT1608346E/pt unknown
- 2004-03-19 EP EP04759681A patent/EP1608346B1/en not_active Expired - Lifetime
- 2004-03-19 AT AT04759681T patent/ATE413865T1/de active
- 2004-03-19 WO PCT/US2004/008417 patent/WO2004093851A1/en active Application Filing
-
2009
- 2009-01-14 CY CY20091100038T patent/CY1108700T1/el unknown
-
2012
- 2012-01-26 JP JP2012013808A patent/JP5592905B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2518918A1 (en) | 2004-11-04 |
PT1608346E (pt) | 2009-02-06 |
CA2518918C (en) | 2011-08-09 |
MXPA05010607A (es) | 2005-11-23 |
ES2317017T3 (es) | 2009-04-16 |
DK1608346T3 (da) | 2009-01-26 |
CY1108700T1 (el) | 2014-04-09 |
WO2004093851A1 (en) | 2004-11-04 |
JP2012136521A (ja) | 2012-07-19 |
US20040191207A1 (en) | 2004-09-30 |
JP5592905B2 (ja) | 2014-09-17 |
EP1608346A1 (en) | 2005-12-28 |
PL1608346T3 (pl) | 2009-07-31 |
ATE413865T1 (de) | 2008-11-15 |
EP1608346B1 (en) | 2008-11-12 |
JP2006522105A (ja) | 2006-09-28 |
DE602004017705D1 (de) | 2008-12-24 |
JP5005339B2 (ja) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
PH12012500765A1 (en) | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | |
RS51764B (en) | TRANSDERMAL PHARMACEUTICAL COMPOSITION | |
PH12015501191A1 (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
UA94052C2 (uk) | Похідні піридазину | |
MEP18208A (en) | Immune response modifier foam formulations | |
TW200621317A (en) | Pharmaceutical composition | |
UA91512C2 (ru) | Коньюгати олигомеров инсулина, их композиция (варианты) и применение | |
TW200728285A (en) | Diacylindazole derivatives as inhibitors of lipases and phospholipases | |
PT1061900E (pt) | Composicoes e metodos para libertacao de uma droga | |
IL179718A0 (en) | Pharmaceutical composition containing irbesartan | |
TW200800987A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
GB9800526D0 (en) | Organic compounds | |
GB2431346B (en) | A combination composition comprising paracetamol and ibuprofen | |
MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
MX2010005714A (es) | Compuestos de piridina. | |
WO2010033726A3 (en) | Drug delivery composition comprising a self-assembled gelator | |
MX2007006775A (es) | Composiciones estables de fenofibrato con esteres de acido graso. | |
MY146444A (en) | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases | |
ATE402706T1 (de) | Im mund zerfallende pharmazeutische zusammensetzung mit risperidon | |
TW200635925A (en) | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents | |
ZA200805598B (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid | |
IL182835A0 (en) | Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents | |
UA95254C2 (ru) | Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит | |
TW200833375A (en) | Pharmaceutical compositions |